NasdaqGS - Nasdaq Real Time Price USD

Halozyme Therapeutics, Inc. (HALO)

38.57 +0.11 (+0.29%)
At close: April 26 at 4:00 PM EDT
37.13 -1.44 (-3.73%)
After hours: April 26 at 7:49 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
829,253.00
829,253.00
660,116.00
443,310.00
267,594.00
Cost of Revenue
192,361.00
192,361.00
139,304.00
81,413.00
43,367.00
Gross Profit
636,892.00
636,892.00
520,812.00
361,897.00
224,227.00
Operating Expense
299,318.00
299,318.00
253,281.00
85,995.00
79,972.00
Operating Income
337,574.00
337,574.00
267,531.00
275,902.00
144,255.00
Net Non Operating Interest Income Expense
-18,762.00
-18,762.00
-16,947.00
-7,526.00
-20,378.00
Other Income Expense
29,517.00
29,517.00
-1,666.00
-19,858.00
5,425.00
Pretax Income
348,329.00
348,329.00
248,918.00
248,518.00
129,302.00
Tax Provision
66,735.00
66,735.00
46,789.00
-154,192.00
217.00
Net Income Common Stockholders
281,594.00
281,594.00
202,129.00
402,710.00
129,085.00
Diluted NI Available to Com Stockholders
281,594.00
281,594.00
202,129.00
402,710.00
129,085.00
Basic EPS
2.13
--
1.48
2.86
0.95
Diluted EPS
2.10
--
1.44
2.74
0.91
Basic Average Shares
131,927.00
--
136,844.00
140,646.00
136,206.00
Diluted Average Shares
134,197.00
--
140,608.00
146,796.00
141,463.00
Total Operating Income as Reported
337,574.00
337,574.00
267,531.00
275,902.00
144,255.00
Total Expenses
491,679.00
491,679.00
392,585.00
167,408.00
123,339.00
Net Income from Continuing & Discontinued Operation
281,594.00
281,594.00
202,129.00
402,710.00
129,085.00
Normalized Income
257,732.05
257,732.05
203,481.84
417,206.34
123,669.10
Interest Expense
18,762.00
18,762.00
16,947.00
7,526.00
20,378.00
Net Interest Income
-18,762.00
-18,762.00
-16,947.00
-7,526.00
-20,378.00
EBIT
367,091.00
367,091.00
265,865.00
256,044.00
149,680.00
EBITDA
451,947.00
451,947.00
315,506.00
259,041.00
152,964.00
Reconciled Cost of Revenue
181,278.00
181,278.00
132,811.00
78,416.00
43,367.00
Reconciled Depreciation
84,856.00
84,856.00
49,641.00
2,997.00
3,284.00
Net Income from Continuing Operation Net Minority Interest
281,594.00
281,594.00
202,129.00
402,710.00
129,085.00
Total Unusual Items Excluding Goodwill
29,517.00
29,517.00
-1,666.00
-19,858.00
5,425.00
Total Unusual Items
29,517.00
29,517.00
-1,666.00
-19,858.00
5,425.00
Normalized EBITDA
422,430.00
422,430.00
317,172.00
278,899.00
147,539.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
5,655.05
5,655.05
-313.16
-5,361.66
9.10
12/31/2020 - 3/16/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GMAB Genmab A/S
28.15
+2.51%
 
IONS Ionis Pharmaceuticals, Inc.
41.59
-0.60%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
INCY Incyte Corporation
51.68
+0.98%
 
UTHR United Therapeutics Corporation
233.85
-0.89%
 
FOLD Amicus Therapeutics, Inc.
10.28
+1.08%
 
EXEL Exelixis, Inc.
23.70
+0.72%
 
LEGN Legend Biotech Corporation
45.30
+1.98%
 
RPRX Royalty Pharma plc
28.00
-0.39%
 
RARE Ultragenyx Pharmaceutical Inc.
44.24
+0.89%